BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib
نویسندگان
چکیده
To take out a personal subscription, please click here More information about Pigment Cell & Melanoma Research at www.pigment.org BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib Marco Ranzani1, Constantine Alifrangis, Daniele Perna, Ken Dutton-Regester, Antonia Pritchard, Kim Wong, Mamunur Rashid, Carla Daniela Robles-Espinoza, Nicholas K. Hayward, Ultan McDermott, Mathew Garnett and David J. Adams
منابع مشابه
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
Melanoma is a disease characterized by lesions that activate ERK. Although 70% of cutaneous melanomas harbor activating mutations in the BRAF and NRAS genes, the alterations that drive tumor progression in the remaining 30% are largely undefined. Vemurafenib, a selective inhibitor of RAF kinases, has clinical utility restricted to BRAF-mutant tumors. MEK inhibitors, which have shown clinical ac...
متن کاملComparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
The NRAS and BRAF genes are frequently mutated in melanoma, suggesting that the NRAS-BRAF-MEK-ERK signaling pathway is an important target for therapy. Two classes of drugs, one targeting activated BRAF and one targeting MEK, are currently undergoing clinical evaluation. We have analysed the NRAS and BRAF mutational status of a series of 44 early passage lines developed from New Zealand patient...
متن کاملActivation and MEK Dependence Loss of NF1 in Cutaneous Melanoma Is Associated with RAS
Melanoma is a disease characterized by lesions that activate ERK. Although 70% of cutaneous melanomas harbor activating mutations in the BRAF and NRAS genes, the alterations that drive tumor progression in the remaining 30% are largely undefined. Vemurafenib, a selective inhibitor of RAF kinases, has clinical utility restricted to BRAF-mutant tumors. MEK inhibitors, which have shown clinical ac...
متن کاملDigoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients
This is the first prospective study of a combination therapy involving a cardenolide and a MEK inhibitor for metastatic melanoma. Whereas BRAF mutant melanomas can exhibit profound responses to treatment with BRAF and MEK inhibitors, there are fewer options for BRAF wild-type melanomas. In preclinical studies, we discovered that cardenolides synergize with MEK inhibitor to promote the regressio...
متن کاملPrenylation Inhibition-Induced Cell Death in Melanoma: Reduced Sensitivity in BRAF Mutant/PTEN Wild-Type Melanoma Cells
While targeted therapy brought a new era in the treatment of BRAF mutant melanoma, therapeutic options for non-BRAF mutant cases are still limited. In order to explore the antitumor activity of prenylation inhibition we investigated the response to zoledronic acid treatment in thirteen human melanoma cell lines with known BRAF, NRAS and PTEN mutational status. Effect of zoledronic acid on proli...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 28 شماره
صفحات -
تاریخ انتشار 2015